lipodystrophy raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
== Medical uses == Flupirtine is used as an analgesic for acute pain, in moderate-to-severe cases. Its muscle relaxant properties make it popular for back pain and other orthopaedic uses, but it is also used for migraines, in oncology, postoperative care, and gynaecology. In 2013 due to issues with liver toxicity, the European Medicines Agency restricted its use to acute pain, for no more than two weeks, and only for people who cannot use other painkillers.
In the above equations, cE and cI are total concentrations of all polypeptides and all polynucleotides, φx and φy are dilution fluxes, ki is the production rate of polypeptide Ei translated from the polynucleotide Ii, and fi is the production rate of polynucleotide Ii synthesised by the complex IiEi-1 (through replication and polymerization). Coupling nucleic acids with proteins in such a model of hypercycle with translation demanded the proper model for the origin of translation code as a necessary condition for the origin of hypercycle organization. At the time of hypercycle theory formulation, two models for the origin of translation code were proposed by Crick and his collaborators. These were models stating that the first codons were constructed according to either an RRY or an RNY scheme, in which R stands for the purine base, Y for pyrimidine, and N for any base, with the latter assumed to be more reliable. Nowadays, it is assumed that the hypercycle model could be realized by utilization of ribozymes without the need for a hypercycle with translation, and there are many more theories about the origin of the genetic code.
=== Corporate self-regulation === AI labs and companies generally abide by safety practices and norms that fall outside of formal legislation. One aim of governance researchers is to shape these norms. Examples of safety recommendations found in the literature include performing third-party auditing, offering bounties for finding failures, sharing AI incidents (an AI incident database was created for this purpose), following guidelines to determine whether to publish research or models, and improving information and cyber security in AI labs. Companies have also made commitments. Cohere, OpenAI, and AI21 proposed and agreed on "best practices for deploying language models", focusing on mitigating misuse. To avoid contributing to racing-dynamics, OpenAI has also stated in their charter that "if a value-aligned, safety-conscious project comes close to building AGI before we do, we commit to stop competing with and start assisting this project" Also, industry leaders such as CEO of DeepMind Demis Hassabis, director of Facebook AI Yann LeCun have signed open letters such as the Asilomar Principles and the Autonomous Weapons Open Letter.
== Biophysical and theoretical methods == Surface plasmon resonance (SPR) is the most common label-free technique for the measurement of biomolecular interactions. SPR instruments measure the change in the refractive index of light reflected from a metal surface (the "biosensor"). Binding of biomolecules to the other side of this surface leads to a change in the refractive index which is proportional to the mass added to the sensor surface. In a typical application, one binding partner (the "ligand", often a protein) is immobilized on the biosensor and a solution with potential binding partners (the "analyte") is channelled over this surface. The build-up of analyte over time allows to quantify on rates (kon), off rates (koff), dissociation constants (Kd) and, in some applications, active concentrations of the analyte. Several different vendors offer SPR-based devices. Best known are Biacore instruments which were the first commercially available. Dual polarisation interferometry (DPI) can be used to measure protein–protein interactions. DPI provides real-time, high-resolution measurements of molecular size, density and mass. While tagging is not necessary, one of the protein species must be immobilized on the surface of a waveguide. As well as kinetics and affinity, conformational changes during interaction can also be quantified. Static light scattering (SLS) measures changes in the Rayleigh scattering of protein complexes in solution and can characterize both weak and strong interactions without labeling or immobilization of the proteins or other biomacromolecule.
Sources: en.wikipedia.org
=== EC 1.1.98 With other, known, acceptors === EC 1.1.98.1: Now EC 1.1.9.1, alcohol dehydrogenase (azurin) EC 1.1.98.2: glucose-6-phosphate dehydrogenase (coenzyme-F420) EC 1.1.98.3: decaprenylphospho-β-D-ribofuranose 2-oxidase EC 1.1.98.3: decaprenylphospho-β-D-ribofuranose 2-dehydrogenase EC 1.1.98.4: F420H2:quinone oxidoreductase EC 1.1.98.5: secondary-alcohol dehydrogenase (coenzyme-F420) EC 1.1.98.6: ribonucleoside-triphosphate reductase (formate) EC 1.1.98.7: serine-type anaerobic sulfatase-maturating enzyme
== Further reading == Whitten, Kenneth W.; Davis, Raymond E; Peck, M. Larry (2002). General chemistry. Fort Worth: Thomson Learning. ISBN 978-0-03-021017-4. Whitten, Kenneth W; Gailey, Kenneth D (1981). General chemistry. Philadelphia: Saunders College Pub. ISBN 978-0-03-057866-3. Petrucci, Ralph H.; Herring, F. Geoffrey; Madura, Jeffry; Bissonnette, Carey; Pearson (2017). General chemistry: principles and modern applications. Toronto: Pearson. ISBN 978-0-13-293128-1. Vogel, Arthur Israel; Furniss, B. S; Tatchell, Austin Robert (1978). Vogel's Textbook of practical organic chemistry. New York: Longman. ISBN 978-0-582-44250-4.
== Pharmacokinetics == The metabolism of topically applied nitrofurazone is thought to be by 5-nitro reduction and cleavage of the -CH=N- linkage to generate a reactive species which can covalently bond to cellular macromolecules, none of the end products are thought to be antimicrobial.
Half-Life E.P. is an EP released by Local H in 2001. It was released as a teaser for their album Here Comes the Zoo, which included the title track. The other songs include two covers, "Static Age" by The Misfits and "25 or 6 to 4" by Chicago, and a b-side, "Stick to What You Know".
Pliny the Elder, in his Natural History, assembled a similarly encyclopaedic account of things in nature, including accounts of many plants and animals. Aristotle, and nearly all Western scholars after him until the 18th century, believed that creatures were arranged in a graded scale of perfection rising from plants on up to humans: the scala naturae or Great Chain of Being. A few scholars in the Hellenistic period under the Ptolemies—particularly Herophilus of Chalcedon and Erasistratus of Chios—amended Aristotle's physiological work, even performing dissections and vivisections. Claudius Galen became the most important authority on medicine and anatomy. Though a few ancient atomists such as Lucretius challenged the teleological Aristotelian viewpoint that all aspects of life are the result of design or purpose, teleology (and after the rise of Christianity, natural theology) would remain central to biological thought essentially until the 18th and 19th centuries. Ernst W. Mayr argued that "Nothing of any real consequence happened in biology after Lucretius and Galen until the Renaissance." The ideas of the Greek traditions of natural history and medicine survived, but they were generally taken unquestioningly in medieval Europe.
Sources: en.wikipedia.org
Additionally, the increased levels of P4 can also cause side effects such as weight gain, fatigue, and mood swings (extreme or rapid changes in mood). In prostate cancer, removal of testicular T through castration (surgical or chemical removal or inactivation of testicles) helps eliminate the growth-promoting effects of androgens. However, in some cases, metastatic tumors can develop into castration-resistant prostate cancer (CRPC). While castration reduces serum T levels by 90-95%, it only decreases DHT in the prostate gland by 50%. This difference between the magnitude of androgen levels confirms that the prostate has enzymes capable of producing DHT even without testicular T. In addition to DHT production within the prostate, researchers found that 11-oxygenated androgens play a role in maintaining total circulating androgen pool levels which are relevant to the amounts of clinically significant androgens in the body. These 11-oxygenated androgens contribute greatly to reactivating androgen signaling in patients with CRPC. 11-oxygenated androgens make up around 60% of the total active androgen pool in such patients. Unlike T or DHT, these levels of 11-oxygenated androgens remain unaffected by castration therapy.
=== Wound state === Wound bed, wound edge and periwound skin should be examined before the initial treatment plan is devised. It should also be re-assessed at each visit or each dressing change. For wound bed, the following parameters are assessed:
== Further reading == Virginia Ott (November 1976). Man with a Million Ideas: Fred Jones, Genius/Inventor. Lerner Publications Company. ISBN 978-0-822-50761-1. Gloria M. Swanson, Margaret V. Ott (1994). I've Got an Idea: The Story of Frederick McKinley Jones (reprint ed.). Lerner Publishing Group. p. 95. ISBN 0-82259-662-8.
== Twelve-Day War == Following the outbreak of the Twelve-Day War, Trump stated that he needed to leave to control the United States's response to the conflict, which meant that he sidelined some scheduled meetings with world leaders. On 16 June 2025, G7 leaders said: "We affirm that Israel has a right to defend itself. We reiterate our support for the security of Israel. Iran is the principal source of regional instability and terror."
The company set up a ghostwriting programme called CASPPER, initially to produce articles about Paxil but which was extended to cover Avandia. As part of the settlement GSK signed a five-year corporate integrity agreement with the Department of Health and Human Services, which obliged the company to make major changes in the way it did business, including changing its compensation programmes for its sales force and executives, and to implement and maintain transparency in its research practices and publication policies. It announced in 2013, that it would no longer pay doctors to promote its drugs or attend medical conferences, and that its sales staff would no longer have prescription targets.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.